Cargando…

Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma

Cisplatin is a first-line chemotherapy drug for lung adenocarcinoma (LUAD). However, its therapeutic efficacy is limited because of serious side effects and acquired drug resistance. Targeting HER2 has been proven to be a viable therapeutic strategy against LUAD. Moreover, inetetamab, an innovative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cui, Jinfang, He, Yuchao, Zhu, Fuyi, Gong, Wenchen, Zuo, Ran, Wang, Yu, Luo, Yi, Chen, Liwei, Wang, Chengmeng, Huo, Gengwei, Lu, Hailing, Liu, Zhiyong, Chen, Peng, Guo, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2023
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496496/ https://www.ncbi.nlm.nih.gov/pubmed/37705753 http://dx.doi.org/10.7150/ijbs.82980

Ejemplares similares

Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
por: Deng, Lan, et al.
Publicado: (2023)

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer: a real-world retrospective study in China
por: Liu, Xiaoyu, et al.
Publicado: (2023)

Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody
por: Liu, Binliang, et al.
Publicado: (2023)

High incidence and reversible bradycardia events following alectinib initiation
por: Yuan, Dongqi, et al.
Publicado: (2022)

The Combination of R848 with Sorafenib Enhances Antitumor Effects by Reprogramming the Tumor Immune Microenvironment and Facilitating Vascular Normalization in Hepatocellular Carcinoma
por: He, Yuchao, et al.
Publicado: (2023)

A Pan-Cancer Analysis of the Oncogenic Role of Twinfilin Actin Binding Protein 1 in Human Tumors
por: Huo, Gengwei, et al.
Publicado: (2021)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

Inhibitors of PD-1 in Non-Small Cell Lung Cancer: A Meta-Analysis of Clinical and Molecular Features
por: Huo, Gengwei, et al.
Publicado: (2022)

Oncogenic role of TWF2 in human tumors: A pan-cancer analysis
por: Liu, Wenjie, et al.
Publicado: (2022)

Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis
por: Liu, Wenjie, et al.
Publicado: (2022)

Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis
por: Huo, Gengwei, et al.
Publicado: (2023)

Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics
por: Liu, Wenjie, et al.
Publicado: (2023)

First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
por: Liu, Wenjie, et al.
Publicado: (2023)

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers
por: Okita, Kouki, et al.
Publicado: (2020)

A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells
por: Liu, Xinlin, et al.
Publicado: (2023)

JSKN003, A NOVEL BIPARATOPIC ANTI-HER2 ANTIBODY-DRUG CONJUGATE, EXHIBITS POTENT ANTITUMOR EFFICACY
por: Wang, Pilin, et al.
Publicado: (2023)

Determining the quantitative relationship between glycolysis and GAPDH in cancer cells exhibiting the Warburg effect
por: Zhu, Xiaobing, et al.
Publicado: (2021)

Potent USP10/13 antagonist spautin‐1 suppresses melanoma growth via ROS‐mediated DNA damage and exhibits synergy with cisplatin
por: Guo, Jia, et al.
Publicado: (2020)

Inetetamab in combination with rapamycin and chemotherapy for trastuzumab‐treated metastatic human epidermal growth factor receptor 2‐positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway
por: Wang, Aijuan, et al.
Publicado: (2023)

Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis
por: Huo, Gengwei, et al.
Publicado: (2023)

First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis
por: Liu, Wenjie, et al.
Publicado: (2023)

CUR5g, a novel autophagy inhibitor, exhibits potent synergistic anticancer effects with cisplatin against non-small-cell lung cancer
por: Chen, Jingxuan, et al.
Publicado: (2022)

Developing a Highly Stable PLGA-mPEG Nanoparticle Loaded with Cisplatin for Chemotherapy of Ovarian Cancer
por: Cheng, Lihua, et al.
Publicado: (2011)

3'-Ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction
por: Fukushima, Hiroto, et al.
Publicado: (2014)

A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity
por: Ding, Xiaoyu, et al.
Publicado: (2020)

Enteromorpha compressa Exhibits Potent Antioxidant Activity
por: Shanab, Sanaa M. M., et al.
Publicado: (2011)

The impact of decreased expression of SVEP1 on abnormal neovascularization and poor prognosis in patients with intrahepatic cholangiocarcinoma
por: Chen, Liwei, et al.
Publicado: (2023)

Microtubule affinity regulating kinase 4 promoted activation of the NLRP3 inflammasome-mediated pyroptosis in periodontitis
por: Wang, Lulu, et al.
Publicado: (2021)

Potent neutralizing monoclonal antibodies against Ebola virus infection
por: Zhang, Qi, et al.
Publicado: (2016)

Network modeling-based identification of the switching targets between pyroptosis and secondary pyroptosis
por: Zhu, Ligang, et al.
Publicado: (2022)

Cochlear Marginal Cell Pyroptosis Is Induced by Cisplatin via NLRP3 Inflammasome Activation
por: Yu, Wenting, et al.
Publicado: (2022)

UCHL1 Is a Putative Tumor Suppressor in Ovarian Cancer Cells and Contributes to Cisplatin Resistance
por: Jin, Chengmeng, et al.
Publicado: (2013)

Conformation-Dependent High-Affinity Potent Ricin-Neutralizing Monoclonal Antibodies
por: Hu, Wei-Gang, et al.
Publicado: (2013)

Sparsomycin Exhibits Potent Antiplasmodial Activity In Vitro and In Vivo
por: Ariefta, Nanang Rudianto, et al.
Publicado: (2022)

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker
por: Chen, Yuning, et al.
Publicado: (2021)

A PLK1 kinase inhibitor enhances the chemosensitivity of cisplatin by inducing pyroptosis in oesophageal squamous cell carcinoma
por: Wu, Mengjiao, et al.
Publicado: (2019)

Ophiopogonin B alleviates cisplatin resistance of lung cancer cells by inducing Caspase-1/GSDMD dependent pyroptosis
por: Cheng, Ziyu, et al.
Publicado: (2022)

Wogonin Alleviates Cisplatin-induced Cardiotoxicity in Mice Via Inhibiting Gasdermin D-mediated Pyroptosis
por: Xu, Jiajun, et al.
Publicado: (2021)

TPGS-1000 exhibits potent anticancer activity for hepatocellular carcinoma in vitro and in vivo
por: Chen, Yidan, et al.
Publicado: (2020)

Review of Cisplatin and Oxaliplatin in Current Immunogenic and Monoclonal Antibody Treatments
por: Mehmood, Rao Khalid
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f9agfgpmfp9iass8hq1rcrfu65